Cell Death News and Research

RSS

Immunomedics reports on ribonuclease-based immunotoxin development at AACR meeting

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported results from two studies on the development of ribonuclease-based immunotoxins at the American Association for Cancer Research conference.

22 Apr 2010

PharmaMar presents new trials with Yondelis, Zalypsis and Irvalec anti-tumor drugs at 101st AACR meeting

PharmaMar, a biopharmaceutical company owned by Grupo Zeltia (ZEL.MC), presented six new trials with marine-based anti-tumor drugs Yondelis(R), Zalypsis(R) and Irvalec(R) at the American Association for Cancer Research's (AACR) 101st Annual Meeting, held in Washington, D.C. from April 17-21.

22 Apr 2010

Findings may illuminate how cancer forms and migrates

Rho proteins have been described as "molecular switches" and play a role in cell migration, cell proliferation, cell death, gene expression, and multiple other common cellular functions.

21 Apr 2010

Researchers identify potential drug target for treatment of Alzheimer's disease

Researchers at the University of Illinois have identified a potential drug target for the treatment of Alzheimer's disease: a receptor that is embedded in the membrane of neurons and other cells.

21 Apr 2010

Researchers use genistein to improve outlook of pancreatic cancer

Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit today presented data at the American Association for Cancer Research's 101st Annual Meeting 2010 that shows when genistein, a component of soy, is paired with the FDA-approved drug oxaliplatin, pancreatic cancer cells become more sensitive to chemotherapy.

20 Apr 2010

Higher intake of vitamin K from dietary sources associated with lower risk of Non-Hodgkin lymphoma

In the first study of vitamin K and Non-Hodgkin lymphoma risk, researchers at the Mayo Clinic campus in Minnesota have found that people who have higher intakes of vitamin K from their diet have a lower risk of developing Non-Hodgkin lymphoma.

20 Apr 2010

Immunomedics develops E1-L-thP1 protein complex for targeted delivery of siRNAs to diverse solid cancers

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported the development of a novel protein complex, designated as E1-L-thP1, for targeted delivery of small interfering ribonucleic acids (siRNAs) to diverse solid cancers.

19 Apr 2010

Multinational phase II study: GS-9450 can reduce markers of liver damage in patients with NASH

Results from a multinational phase II study presented today at the International Liver CongressTM 2010 have shown that treatment with the caspase inhibitor GS-9450 can reduce markers of liver damage in patients with non-alcoholic steatohepatitis (NASH - the most serious form of non-alcoholic liver disease) as demonstrated by reduced levels of alanine and aspartate aminotransferases, hepatic enzymes that indicate cell damage.

17 Apr 2010

Investigational treatment with IGIV reduces brain atrophy in Alzheimer's patients

An investigational intervention using naturally ocurring antibodies in human blood has preserved the thinking abilities of a group of mild- to moderate-stage Alzheimer's patients over 18 months and significantly reduced the rate of atrophy (shrinkage) of their brains, according to a study performed at the NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

15 Apr 2010

Targeted therapy MDV3100 is effective for patients with CRPC: Study

An experimental drug is showing promise for the treatment of men with an aggressive form of advanced prostate cancer. A new multicenter study has concluded that the targeted therapy MDV3100 is safe and effective for patients with castration-resistant prostate cancer, known for its poor prognosis and limited treatment options.

15 Apr 2010

High level of microRNAs found in patients with high-risk multiple myeloma

Multiple myeloma researchers at the University of Arkansas for Medical Sciences (UAMS) recently discovered that widespread activity of a specific class of genes can identify aggressive, or high-risk, cases of the disease.

13 Apr 2010

Stress hormones may suppress tumor growth: Study

Chronic stress triggers a chain of molecular events that protects breakaway ovarian cancer cells from destruction, a team of researchers led by scientists at The University of Texas M. D. Anderson Cancer Center reports April 12 in the early online publication of the Journal of Clinical Investigation.

13 Apr 2010

Overcoming resistance - new options for the treatment of ovarian cancer

Research on the development of a new therapeutic agent for the treatment of particularly aggressive ovarian cancer has produced some very promising initial findings. In laboratory tests, scientists have succeeded in reducing the resistance of the tumour cells to a natural resistance mechanism with the help of a monoclonal antibody. The results of this project, which was funded by the Austrian Science Fund FWF, have just been published. The project also succeeded in establishing a hitherto unknown connection between so-called "natural killer cells" and the regulated death of cancer cells.

12 Apr 2010

UCCS, Texas A&M Health Science Center announce collaboration in bioenergetics, immunology and cell life

The University of Colorado at Colorado Springs will work collaboratively with the Texas A&M Health Science Center in the areas of bioenergetics, immunology and cell life, according to a memorandum of understanding between the two schools announced Monday, April 10.

12 Apr 2010

Accumulation of mutated protein may explain damaging cellular behavior in Huntington's disease

In a step towards a possible treatment for Huntington's disease, scientists at Albert Einstein College of Medicine of Yeshiva University have shown for the first time that the accumulation of a mutated protein may explain damaging cellular behavior in Huntington's disease. Their research is described in the April 11 online edition of Nature Neuroscience.

12 Apr 2010

SRU Biosystems receives Notice of Allowance to perform cellular assays on optical label-free biosensors

SRU Biosystems, a leader in highly sensitive label-free detection technologies, today announced the issuance of a Notice of Allowance from the US Patent Office for claims on a fundamental patent application, US Patent Application No. 11/635,934, for performing cellular assays on optical label-free biosensors.

12 Apr 2010

Gamma-tocotrienol kills prostate tumour cells in animal model studies

Researchers from Davos Life Science in Singapore, in collaboration with scientists at the University of Hong Kong, have shown that gamma-tocotrienol, a member of the vitamin E family, is potent in killing prostate tumour cells in animal model studies. This research was reported this week in the latest edition of Pharmacology.

9 Apr 2010

Potential toxicity of zinc nanoparticles in sunscreen products

Scientists are reporting that particle size affects the toxicity of zinc oxide, a material widely used in sunscreens. Particles smaller than 100 nanometers are slightly more toxic to colon cells than conventional zinc oxide. Solid zinc oxide was more toxic than equivalent amounts of soluble zinc, and direct particle to cell contact was required to cause cell death. Their study is in ACS' Chemical Research in Toxicology, a monthly journal.

8 Apr 2010

Role of beta defensins in development of chronic inflammatory response in the brain

Researchers at the Case Western Reserve University School of Dental Medicine and School of Medicine will look for evidence within the brain for human beta defensin peptide function-proteins important to the peripheral body's natural defense system against infection from the outside environment.

8 Apr 2010

Calistoga Pharmaceuticals commences CAL-101 trial in combination with Rituxan and/or Treanda

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the initiation of a Phase 1 trial of CAL-101, the Company's oral, PI3K delta inhibitor, in combination with standard of care agents Rituxan® (rituximab) and/or Treanda® (bendamustine) in patients with relapsed or refractory indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.

7 Apr 2010

Cell Death News and Research

Immunomedics reports on ribonuclease-based immunotoxin development at AACR meeting

PharmaMar presents new trials with Yondelis, Zalypsis and Irvalec anti-tumor drugs at 101st AACR meeting

Findings may illuminate how cancer forms and migrates

Researchers identify potential drug target for treatment of Alzheimer's disease

Researchers use genistein to improve outlook of pancreatic cancer

Higher intake of vitamin K from dietary sources associated with lower risk of Non-Hodgkin lymphoma

Immunomedics develops E1-L-thP1 protein complex for targeted delivery of siRNAs to diverse solid cancers

Multinational phase II study: GS-9450 can reduce markers of liver damage in patients with NASH

Investigational treatment with IGIV reduces brain atrophy in Alzheimer's patients

Targeted therapy MDV3100 is effective for patients with CRPC: Study

High level of microRNAs found in patients with high-risk multiple myeloma

Stress hormones may suppress tumor growth: Study

Overcoming resistance - new options for the treatment of ovarian cancer

UCCS, Texas A&M Health Science Center announce collaboration in bioenergetics, immunology and cell life

Accumulation of mutated protein may explain damaging cellular behavior in Huntington's disease

SRU Biosystems receives Notice of Allowance to perform cellular assays on optical label-free biosensors

Gamma-tocotrienol kills prostate tumour cells in animal model studies

Potential toxicity of zinc nanoparticles in sunscreen products

Role of beta defensins in development of chronic inflammatory response in the brain

Calistoga Pharmaceuticals commences CAL-101 trial in combination with Rituxan and/or Treanda

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News